Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

@article{Kimby2008LongtermMR,
  title={Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.},
  author={Eva K Kimby and Jesper Jurlander and Christian Hartman Geisler and Hans Hagberg and Harald H. Holte and Tuula Lehtinen and Bj{\"o}rn Ostenstad and Mads E. Hansen and Anders Osterborg and Ola Lind{\'e}n and Christer Sundstr{\"o}m},
  journal={Leukemia & lymphoma},
  year={2008},
  volume={49 1},
  pages={102-12}
}
The purpose of this phase II randomized trial was to evaluate the effect and safety of interferon-alpha2a (IFN) in combination with extended dosing rituximab in patients with symptomatic, advanced indolent lymphoma responding to a standard single course of rituximab. Totally 123 patients were treated with rituximab 375 mg/m2 once weekly for 4 weeks leading to 14 complete response (CR; 11%), 56 partial response (PR; 46%), and 13 minor responses (MR; 11%). Patients achieving either PR or MR were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…